Cognitive-behavioral Treatment for Rheumatoid Arthritis
Not Applicable
- Conditions
- Rheumatoid Arthritis
- Registration Number
- NCT02257073
- Lead Sponsor
- Chengdu PLA General Hospital
- Brief Summary
To evaluate the effectiveness of Cognitive-behavioral treatment for people with rheumatoid arthritis
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 150
Inclusion Criteria
- diagnosed by rheumatology consultants with RA
Exclusion Criteria
- severe psychological difficulties
- currently receiving mental health care
- any medical condition that might prevent them from safely exercising (e.g. history of more severe heart, lung or cerebrovascular disease)
- previously attended an education programme
- had a Modified Health Assessment Questionnaire score >2 (score range 0-3), that is severe functional problems
- history of organic brain syndrome
- presence of a psychotic disorder
- presence of other uncontrolled medical disorders
- presence of a major communication disorder, illiteracy
- presence of less than an 8th grade education (due to inability to complete questionnaires)
- presence of a therapeutic dosage of an antidepressant medication, or presence of another autoimmune disease/disabling condition
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Changes from baseline in disease activity score in 28 joints(DAS28) at 48 weeks at 0 week, 12 weeks, 24 weeks, 48 weeks
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie cognitive-behavioral therapy's impact on rheumatoid arthritis inflammation pathways?
How does cognitive-behavioral treatment compare to standard DMARDs in managing RA disease activity and joint damage progression?
Which biomarkers correlate with response to cognitive-behavioral interventions in rheumatoid arthritis patients?
What are the long-term adverse event profiles of cognitive-behavioral therapy versus pharmacological RA treatments?
Are there synergistic effects when combining cognitive-behavioral therapy with biologic agents like TNF inhibitors in RA management?
Trial Locations
- Locations (1)
General Hospital of Chengdu Military Area Command PLA
🇨🇳Chengdu, Sichuan, China
General Hospital of Chengdu Military Area Command PLA🇨🇳Chengdu, Sichuan, China
